Tyra Biosciences (TYRA) Liabilities and Shareholders Equity (2020 - 2026)

Tyra Biosciences (TYRA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $412.0 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 19.96% year-over-year to $412.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 10.95% YoY) and the FY2025 annual result came in at $282.6 million, down 22.27% from the prior year.
• Liabilities and Shareholders Equity rose to $412.0 million in Q1 2026, from $282.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $412.0 million in Q1 2026 to a low of $225.9 million in Q4 2023.
• A 5-year average of $311.8 million and a median of $299.0 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity surged 60.97% — and 2025, when it fell 22.27%.
• Tracing TYRA's Liabilities and Shareholders Equity over 5 years: stood at $266.2 million in 2022, then slipped by 15.15% to $225.9 million in 2023, then surged by 60.97% to $363.6 million in 2024, then slipped by 22.27% to $282.6 million in 2025, then surged by 45.8% to $412.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $412.0 million (Q1 2026), $282.6 million (Q4 2025), and $301.9 million (Q3 2025), per Business Quant data.